Wobble Base BioResearch®

WB IG Gene Rearrangement Detection Kit (IGHV Mutation load Analysis) [PCR-DNA Sequencing based; require Sanger sequencing Platform]

OUR CERTIFICATIONS

Our certifications

✓ ISO 13486:2016 certified

✓ ISO 9001: 2015 certified

✓ DPIIT (Govt. of India) certified

✓ Institutional Biosafety Committee (DBT)

✓ MSME Registered

✓ Trademark Registered with Trade Mark, Registry, Govt. of India

CONTACT

PHONE:
+91-6353339602

WEBSITE:
Wobblebase.in

EMAIL:
support@wobblebase.in

GRANTS/AWARDS

- ✓ Biotechnology Ignition Grant Award-2013
- ✓ Grand Challenge-TB Control - Bill and Melinda Gates Foundation| USAID | BIRAC, Govt. of India Phase-1 Grant -2015;
- ✓ Grand Challenge-TB Control - Bill and Melinda Gates Foundation| USAID | BIRAC, Govt. of India Phase 2 Grant-2017
- ✓ Grand Challenge Explorations- Bill and Melinda Gates Foundation | USAID | BIRAC, Govt. of India Grant-2017
- ✓ DBS-NUS Social Venture Challenge Asia 2017 Finalist.
- ✓ BIRAC (Dept. of Biotechnology) Pre- Accelerator MedTech Challenge Grant-2021
- ✓ Fastest Growing Indian Company Award (2019) – International Achievers Conference, Bangkok
- ✓ Small Business Innovation Research Initiative (SBIRI) (2013) – Dept. of Science and Tech., Govt. of India.

INTRODUCTION

- The IGHV gene mutation detection is a highly specialized test that is often recommended in the management of certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL) and some types of non-Hodgkin lymphoma (NHL).
- The test analyzes the status of mutations in the Immunoglobulin Heavy Chain Variable Region (IGHV) gene, which provides valuable prognostic information for these diseases. This test helps physicians to tailor treatments and predict the likely course of the disease more accurately.
- Mutations in the IGHV gene are a natural process that occurs in healthy B-cells (a type of white blood cell) during the immune response. However, when these mutated B-cells become cancerous, their IGHV mutation status can have a significant impact on the course of the disease.
- Our Sanger sequencing-based approach enables precise detection and characterization of Ig gene rearrangements and oncogenic translocations, allowing for comprehensive assessment of B cell neoplasm heterogeneity. With unparalleled sensitivity and specificity, Sanger sequencing offers a gold standard method for identifying clonal immunoglobulin gene rearrangements and aberrant translocations, guiding clinical decision-making and prognostic evaluation.

KEY FEATURES

- Comprehensive Analysis: Detection of Ig gene rearrangements and oncogenic translocations for thorough characterization of B cell neoplasms.
- High Sensitivity: Reliable detection of clonal populations and rare genetic events with exceptional sensitivity.
- Clinical Relevance: Stratification of patients based on distinct genetic profiles to inform prognosis and treatment selection.
- Expert Interpretation: Interpretation of sequencing data by experienced molecular pathologists to ensure accurate and clinically actionable results.

WB IG Gene Rearrangement Detection Kit (IGHV Mutation load Analysis) [PCR-DNA Sequencing based; require Sanger sequencing Platform]

✓ TATA Health Fund (Phase 1 - Biosafety) – 2024

- Customized Solutions: Tailored testing strategies to meet specific clinical and research needs, including panel design and result reporting options.

Your thinking partner in science

SPECIFICATIONS

Technology	Conventional nested PCR amplification and Sanger DNA Sequencing
Type of Analysis	Qualitative
Target Sequence	Variable region of the immunoglobulin heavy chain (IGHV) gene
Controls	Positive control
Validated specimen	Whole blood)
Storage	-20 ± 5 °C
Required detection channels	FAM, HEX(VIC)
Instrument	Compatible with a wide range of conventional PCR devices and ABI-DNA capillary electrophoresis sequencing

CATALOG NUMBER	PRODUCT INFORMATION	CATALOG NUMBER
IGVHDS/WBB/50	WB IG Gene Rearrangement PCR Detection Kit	50 reactions
IGVHDS/WBB/100	WB IG Gene Rearrangement PCR Detection Kit	100 reactions